IN8bio reports Q1 2025 net loss of $5.6M; INB-100 shows 100% AML relapse-free at 20.1 months

IN8BIO, INC.

2025-Q1 EPS reported -$0.07

Net loss $5.6M ($0.07/sh) vs. $8.6M ($0.20/sh) prior year; cash $11.9M as of March 31, 2025.
Phase 1 INB-100 data: 100% AML patients relapse-free at median 20.1 months follow-up; no CRS/ICANs.
Presented INB-600 TCE platform at AACR 2025 showing picomolar potency and minimal cytokine release.
Upcoming oral presentation at ASCO 2025 for INB-200 in glioblastoma (May 30, 2025).
Raised ~$4.1M net from ATM and warrant exercises in Q1 2025; additional $1.9M gross in April 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.